Travere Therapeutics share price logo

Travere Therapeutics

NASDAQ: TVTX

Mid Cap

$62.76

-1.98

(-3.06%)

as on

Travere Therapeutics Stock Performance

as on September 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $62.47
    $64.89
    downward going graph

    0.46%

    Downside

    3.39%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $22.06
    $68.73
    downward going graph

    64.86%

    Downside

    9.51%

    Upside

    downward going graph

Travere Therapeutics share price movements today

Previous Close
$64.74
Open
$64.71
Volume
632.6K
Market Cap
$6.0B
Day's Low - High
$62.47 - $64.89
52 Week Low - High
$22.06 - $68.73

Travere Therapeutics Historical Returns

1 Month Return
-1.85 %
3 Month Return
+ 17.39 %
1 Year Return
+ 160.52 %
3 Year Return
+ 391.2 %
5 Year Return
+ 187.61 %

Travere Therapeutics Stock Fundamentals & Key Indicators

Check Travere Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.0B

EPS (TTM)

1.7416

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-

Revenue (TTM)

-

Profit Margin

-7.35%

Return On Equity TTM

-236.36%

Travere Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Travere Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$6.0B187.61%NA-7.35%0.00%
BUY$63.1B-63.24%-19.81-12.57%0.00%
BUY$130.1B174.21%29.8186.04%0.00%
BUY$79.7B21.1%18.4884.86%0.48%

Stock Returns calculator for Travere Therapeutics Stock including INR - Dollar returns

The Travere Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Travere Therapeutics investment value today

Current value as on today

₹2,74,858

Returns

₹1,74,858

(+174.86%)

Returns from Travere Therapeutics Stock

₹1,52,555 (+152.56%)

Dollar Impact

₹22,303 (+22.3%)

Analyst Recommendation on Travere Therapeutics Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.66666666666666% of analysts recommend a 'BUY' rating for Travere Therapeutics. Average target price of $74.21

Travere Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Travere Therapeutics.

What analysts predicted

15.43%UPSIDE

Target Price

$74.21

Current Price

$62.76

Analyzed by

12 Analysts

Target

$74.21

Travere Therapeutics target price $74.21, a slight upside of 15.43% compared to current price of $62.76. According to 12 analysts rating.

Indian Investors' Interest in Travere Therapeutics Stock

Search interest for Travere Therapeutics Stock has increased by 44% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:44% versus previous 30 day period

Travere Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
41
54
62
74
81
114
164
129
127
169
Gross Profit
39
41
61
72
77
112
163
127
100
167
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-136
-70
-54
-60
-41
-12
25
2
-37
-34
Net Profit Margin
-328.86%
-130.11%
-87.14%
-80.58%
-50.44%
-11.14%
15.59%
2.10%
-29.17%
-20.52%

Travere Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
133
154
164
175
198
131
109
145
233
490
Gross Profit
129
151
158
170
192
128
105
133
225
480
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-47
-59
-102
-146
-169
-180
-278
-111
-321
-25
Net Profit Margin
-35.86%
-38.55%
-62.51%
-83.51%
-85.43%
-136.60%
-254.41%
-76.70%
-137.90%
-5.21%

Mutual Funds that own Travere Therapeutics Stock

Check out the Mutual Funds with significant holdings in Travere Therapeutics.

Funds
Holdings
Shares Held
Delaware Group Equity Funds V
9.513854%
8967863
VANGUARD INDEX FUNDS
4.189347%
3948924
Fidelity Rutland Square Trust II
3.631877%
3423447
JANUS INVESTMENT FUND
3.325511%
3134663
Fidelity Securities Fund
2.597946%
2448853

Global Institutional Holdings in Travere Therapeutics

Funds
Holdings
Vanguard
5.26%
iShares
4.7%
Joseph Edelman
3.98%
SPDR
2.73%
Richard Driehaus
1.53%

Travere Therapeutics News & Key Events

  • img

    Today's Timeline - 13 January

    Tue, 06:03 PM

    -

    Travere Therapeutics stock tumbled 28% after FDA requested additional information on a kidney disorder drug's clinical benefits.

    Tue, 06:34 PM

    -

    Shares of Travere fell 28.2% in pre-market after issuing a corporate update and 2026 outlook.

    Tue, 11:07 PM

    -

    Biopharma stock tumbled 32% following FDA's request for more information on kidney disorder drug.

Insights on Travere Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, TVTX stock has moved up by 133.8%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -37.10M → -34.79M (in $), with an average increase of 6.6% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, TVTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 127.19M → 169.58M (in $), with an average increase of 25.0% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 510.3% return, outperforming this stock by 357.7%

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
OrganisationTravere Therapeutics
Headquarters3611 Valley Centre Drive, San Diego, CA, 92130, US
IndustryBiotechnology
CEOEric Dube
E-voting on sharesClick here to vote

Key Management of Travere Therapeutics

Name

Title

Dr. Eric M. Dube Ph.D.

President, CEO & Director

Dr. Jula Inrig M.D.

Executive VP, Head of Research & Development and Chief Medical Officer

Ms. Nivi Nehra

Vice President of Corporate Communications & Investor Relations

Mr. Casey Logan

Chief Business Officer

Ms. Elizabeth E. Reed J.D.

Chief Legal Officer, General Counsel & Secretary

Ms. Angela Giannantonio

Chief People Officer

Mr. Christopher Cline C.F.A.

Chief Financial Officer

Dr. William E. Rote Ph.D.

Chief Research Officer

Mr. Peter Heerma

Chief Commercial Officer

Ms. Sandra Calvin

SVP & Chief Accounting Officer

FAQs

What is Travere Therapeutics share price today?

Travere Therapeutics share price today is $62.76 as on at the close of the market. Travere Therapeutics share today touched a day high of $64.89 and a low of $62.47.

What is the 52 week high and 52 week low for Travere Therapeutics share?

Travere Therapeutics share touched a 52 week high of $68.73 on and a 52 week low of $22.06 on . Travere Therapeutics stock price today i.e. is closed at $62.76,which is 8.69% down from its 52 week high and 184.56% up from its 52 week low.

What is Travere Therapeutics's market capitalisation today?

Travere Therapeutics market capitalisation is $0.01T as on .

How to invest in Travere Therapeutics Stock (TVTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Travere Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Travere Therapeutics Shares that will get you 0.0239 shares as per Travere Therapeutics share price of $62.76 per share as on September 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Travere Therapeutics Stock (TVTX) from India?

Indian investors can start investing in Travere Therapeutics (TVTX) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.80 in Travere Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Travere Therapeutics share’s latest price of $62.76 as on September 19, 2026 at 8:45 am IST, you will get 0.1593 shares of Travere Therapeutics. Learn more about fractional shares .

What are the returns that Travere Therapeutics has given to Indian investors in the last 5 years?

Travere Therapeutics stock has given 187.61% share price returns and 30.29% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?